|
1
|
Lopez-Barcons L, Maurer BJ, Kang MH and
Reynolds CP: P450 inhibitor ketoconazole increased the intratumor
drug levels and antitumor activity of fenretinide in human
neuroblastoma xenograft models. Int J Cancer. 141:405–413. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Agarwal SK, Salem AH, Danilov AV, Hu B,
Puvvada S, Gutierrez M, Chien D, Lewis LD and Wong SL: Effect of
ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of
venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin
lymphoma. Br J Clin Pharmacol. 83:846–854. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Figg WD, Woo S, Zhu W, Chen X, Ajiboye AS,
Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, et al: A
phase I clinical study of high dose ketoconazole plus weekly
docetaxel for metastatic castration resistant prostate cancer. J
Urol. 183:2219–2226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hsin IL, Ou CC, Wu TC, Jan MS, Wu MF, Chiu
LY, Lue KH and Ko JL: GMI, an immunomodulatory protein from
Ganoderma microsporum, induces autophagy in non-small cell
lung cancer cells. Autophagy. 7:873–882. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin CH, Hsiao YM, Ou CC, Lin YW, Chiu YL,
Lue KH, Chang JG and Ko JL: GMI, a Ganoderma immunomodulatory
protein, down-regulates tumor necrosis factor α-induced expression
of matrix metalloproteinase 9 via NF-κB pathway in human alveolar
epithelial A549 cells. J Agric Food Chem. 58:12014–12021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chiu LY, Hu ME, Yang TY, Hsin IL, Ko JL,
Tsai KJ and Sheu GT: Immunomodulatory protein from Ganoderma
microsporum induces pro-death autophagy through Akt-mTOR-p70S6K
pathway inhibition in multidrug resistant lung cancer cells. PLoS
One. 10:e01257742015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hsin IL, Ou CC, Wu MF, Jan MS, Hsiao YM,
Lin CH and Ko JL: GMI, an immunomodulatory protein from
Ganoderma microsporum, potentiates cisplatin-induced
apoptosis via autophagy in lung cancer cells. Mol Pharm.
12:1534–1543. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang TY, Yu CC, Hsieh PL, Liao YW, Yu CH
and Chou MY: GMI ablates cancer stemness and cisplatin resistance
in oral carcinomas stem cells through IL-6/Stat3 signaling
inhibition. Oncotarget. 8:70422–70430. 2017.PubMed/NCBI
|
|
9
|
Hardie DG: AMPK: Positive and negative
regulation, and its role in whole-body energy homeostasis. Curr
Opin Cell Biol. 33:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roy I, McAllister DM, Gorse E, Dixon K,
Piper CT, Zimmerman NP, Getschman AE, Tsai S, Engle DD, Evans DB,
et al: Pancreatic cancer cell migration and metastasis is regulated
by chemokine-biased agonism and bioenergetic signaling. Cancer Res.
75:3529–3542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qiao L, Zheng J, Jin X, Wei G, Wang G, Sun
X and Li X: Ginkgolic acid inhibits the invasiveness of colon
cancer cells through AMPK activation. Oncol Lett. 14:5831–5838.
2017.PubMed/NCBI
|
|
12
|
Kalbasi A, Komar C, Tooker GM, Liu M, Lee
JW, Gladney WL, Ben-Josef E and Beatty GL: Tumor-derived CCL2
mediates resistance to radiotherapy in pancreatic ductal
adenocarcinoma. Clin Cancer Res. 23:137–148. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang AL, Miska J, Wainwright DA, Dey M,
Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, et al:
CCL2 produced by the glioma microenvironment is essential for the
recruitment of regulatory T cells and myeloid-derived suppressor
cells. Cancer Res. 76:5671–5682. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS and
Lim JS: Berberine-induced AMPK activation inhibits the metastatic
potential of melanoma cells via reduction of ERK activity and COX-2
protein expression. Biochem Pharmacol. 83:385–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gazzaniga S, Bravo AI, Guglielmotti A, van
Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J and Wainstok
R: Targeting tumor-associated macrophages and inhibition of MCP-1
reduce angiogenesis and tumor growth in a human melanoma xenograft.
J Invest Dermatol. 127:2031–2041. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mitra R and Goodman OB Jr: CYP3A5
regulates prostate cancer cell growth by facilitating nuclear
translocation of AR. Prostate. 75:527–538. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lim SM, Hwang JW, Ahn JB, Bae SK, Park CH,
Kim KY, Rha SY, Chung HC, Roh JK and Shin SJ: Combination of CYP
inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on
ERK in BRAF mutant colon cancer cells. Anticancer Res.
33:2499–2508. 2013.PubMed/NCBI
|
|
18
|
Venkatakrishnan K, Rader M, Ramanathan RK,
Ramalingam S, Chen E, Riordan W, Trepicchio W, Cooper M, Karol M,
von Moltke L, et al: Effect of the CYP3A inhibitor ketoconazole on
the pharmacokinetics and pharmacodynamics of bortezomib in patients
with advanced solid tumors: A prospective, multicenter, open-label,
randomized, two-way crossover drug-drug interaction study. Clin
Ther 31 Pt. 2:2444–2458. 2009. View Article : Google Scholar
|
|
19
|
Sella A, Kilbourn R, Amato R, Bui C,
Zukiwski AA, Ellerhorst J and Logothetis CJ: Phase II study of
ketoconazole combined with weekly doxorubicin in patients with
androgen-independent prostate cancer. J Clin Oncol. 12:683–688.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eklund J, Kozloff M, Vlamakis J, Starr A,
Mariott M, Gallot L, Jovanovic B, Schilder L, Robin E, Pins M and
Bergan RC: Phase II study of mitoxantrone and ketoconazole for
hormone-refractory prostate cancer. Cancer. 106:2459–2465. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Patel K, Patil A, Mehta M, Gota V and
Vavia P: Oral delivery of paclitaxel nanocrystal (PNC) with a dual
Pgp-CYP3A4 inhibitor: Preparation, characterization and antitumor
activity. Int J Pharm. 472:214–223. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Namiki T, Tanemura A, Valencia JC, Coelho
SG, Passeron T, Kawaguchi M, Vieira WD, Ishikawa M, Nishijima W,
Izumo T, et al: AMP kinase-related kinase NUAK2 affects tumor
growth, migration, and clinical outcome of human melanoma. Proc
Natl Acad Sci USA. 108:6597–6602. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cerezo M, Tichet M, Abbe P, Ohanna M,
Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P,
Bertolotto C, et al: Metformin blocks melanoma invasion and
metastasis development in AMPK/p53-dependent manner. Mol Cancer
Ther. 12:1605–1615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fediuc S, Gaidhu MP and Ceddia RB:
Regulation of AMP-activated protein kinase and acetyl-CoA
carboxylase phosphorylation by palmitate in skeletal muscle cells.
J Lipid Res. 47:412–420. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Knight DA, Ngiow SF, Li M, Parmenter T,
Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, et al: Host
immunity contributes to the anti-melanoma activity of BRAF
inhibitors. J Clin Invest. 123:1371–1381. 2013. View Article : Google Scholar : PubMed/NCBI
|
